Log in to save to my catalogue

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6810613

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

About this item

Full title

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

Publisher

New York: Nature Publishing Group US

Journal title

Nature medicine, 2019-03, Vol.25 (3), p.462-469

Language

English

Formats

Publication information

Publisher

New York: Nature Publishing Group US

More information

Scope and Contents

Contents

Immune checkpoint inhibitors have been successful across several tumor types; however, their efficacy has been uncommon and unpredictable in glioblastomas (GBM), where <10% of patients show long-term responses. To understand the molecular determinants of immunotherapeutic response in GBM, we longitudinally profiled 66 patients, including 17 long-te...

Alternative Titles

Full title

Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6810613

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6810613

Other Identifiers

ISSN

1078-8956

E-ISSN

1546-170X

DOI

10.1038/s41591-019-0349-y

How to access this item